Lithium-Induced Dysgeusia and Hyposmia: A Case Report and a Literature Review.

IF 0.8 4区 医学 Q4 CLINICAL NEUROLOGY Clinical Neuropharmacology Pub Date : 2023-01-01 DOI:10.1097/WNF.0000000000000531
Odete Nombora, Ana Samico, Ângela Venâncio
{"title":"Lithium-Induced Dysgeusia and Hyposmia: A Case Report and a Literature Review.","authors":"Odete Nombora,&nbsp;Ana Samico,&nbsp;Ângela Venâncio","doi":"10.1097/WNF.0000000000000531","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bipolar disorder is a complex psychiatric disorder where long-term treatment is crucial to maintain stabilization. Although largely well tolerated, lithium has a wide spectrum of adverse effects in different organs and seems to also cause taste and smell disorders, which remain rare and not largely described. We aim to present a rare case of hyposmia and dysgeusia secondary to lithium treatment in a bipolar patient and also conduct a review on these rare lithium adverse effects.</p><p><strong>Case presentation: </strong>The case is a 43-year-old woman with type I bipolar disorder who became stabilized and fully functional with lithium therapy. After 4 months of treatment, she began to notice progressive hyposmia and dysgeusia. After multiple diagnostic and screening tests, lithium was implicated as the cause of the symptoms, which led to a switch to valproic acid. After 3 months, she was not compensated with valproic acid treatment, returned to lithium therapy despite its adverse effects, and became stabilized again.</p><p><strong>Conclusions: </strong>There are few data on lithium therapy taste and smell adverse effects. Most studies on this topic are likely to be case reports. Lithium therapy may cause dysgeusia and hyposmia, although mechanisms are not fully understood. These adverse effects can interfere negatively in patient's treatment adherence. Therefore, physicians who prescribe lithium should be aware of them. Further structured studies are needed to better understand these lithium rare adverse effects and the appropriate way to assess and monitoring them.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"46 1","pages":"31-33"},"PeriodicalIF":0.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000531","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Bipolar disorder is a complex psychiatric disorder where long-term treatment is crucial to maintain stabilization. Although largely well tolerated, lithium has a wide spectrum of adverse effects in different organs and seems to also cause taste and smell disorders, which remain rare and not largely described. We aim to present a rare case of hyposmia and dysgeusia secondary to lithium treatment in a bipolar patient and also conduct a review on these rare lithium adverse effects.

Case presentation: The case is a 43-year-old woman with type I bipolar disorder who became stabilized and fully functional with lithium therapy. After 4 months of treatment, she began to notice progressive hyposmia and dysgeusia. After multiple diagnostic and screening tests, lithium was implicated as the cause of the symptoms, which led to a switch to valproic acid. After 3 months, she was not compensated with valproic acid treatment, returned to lithium therapy despite its adverse effects, and became stabilized again.

Conclusions: There are few data on lithium therapy taste and smell adverse effects. Most studies on this topic are likely to be case reports. Lithium therapy may cause dysgeusia and hyposmia, although mechanisms are not fully understood. These adverse effects can interfere negatively in patient's treatment adherence. Therefore, physicians who prescribe lithium should be aware of them. Further structured studies are needed to better understand these lithium rare adverse effects and the appropriate way to assess and monitoring them.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
锂诱发的听力障碍和听力减退:1例报告和文献复习。
背景:双相情感障碍是一种复杂的精神障碍,长期治疗对维持稳定至关重要。虽然在很大程度上耐受性良好,但锂在不同器官中有广泛的不良影响,似乎还会导致味觉和嗅觉障碍,这种情况仍然很少见,也没有大量描述。我们的目的是报告一例罕见的双相患者锂治疗后继发的低氧和嗅觉障碍,并对这些罕见的锂不良反应进行回顾。病例介绍:该病例是一名43岁女性I型双相情感障碍患者,经锂治疗后病情稳定,功能完全正常。治疗4个月后,她开始注意到进行性睡眠不足和发音困难。经过多次诊断和筛选测试,锂被认为是导致症状的原因,这导致改用丙戊酸。3个月后,患者未补用丙戊酸治疗,尽管有不良反应,但仍恢复锂治疗,病情再次稳定。结论:关于锂离子治疗味觉和嗅觉不良反应的资料较少。关于这一主题的大多数研究可能是病例报告。锂离子治疗可能导致读写困难和低氧,尽管其机制尚不完全清楚。这些不良反应会对患者的治疗依从性产生负面影响。因此,开锂处方的医生应该注意这一点。需要进一步的结构化研究来更好地了解这些锂罕见的副作用以及评估和监测它们的适当方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Neuropharmacology
Clinical Neuropharmacology 医学-临床神经学
CiteScore
1.20
自引率
10.00%
发文量
63
审稿时长
6-12 weeks
期刊介绍: Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.
期刊最新文献
Translational Neuroscience Contributes to Understanding Neurodevelopmental Outcomes of Dostoyevsky's "Brothers Karamazov" With Treatment Implications. Pharmacological Management of Acute and Chronic Insomnia: A Cross-Sectional Study. A Retrospective Study on Botulinum Toxin Injection in Patients With Multiple Sclerosis Related Tremor: A Treatment Option Worth Trying. Molecular Docking Analysis Reveals the Promising Role of Apigenin as a Potential Treatment for Neurological Disorders. A Real-World Experience of Rituximab: A Panacea in Therapy of Multiple Sclerosis in Low- and Middle-Income Setting.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1